Health “We understand that this may be difficult news for some of our patients,” Mass General Brigham said in a statement. Henry Magendantz, a participant in the Aduhelm clinical trial, received an infusion in Providence back in May.
September 28, 2021
Mass General Brigham, the state’s largest health care provider, said Tuesday that it will not administer Biogen’s controversial new Alzheimer’s drug to patients, dealing another setback to the Cambridge company and its expensive treatment.
The network, which includes the flagships Massachusetts General
→ Continue reading at Boston - Health